Aeras Global TB Vaccine Foundation Announces Appointment of Accomplished Pharmaceutical Executive as President and CEO
James E. Connolly Committed to Accelerating the Development of New Vaccines to Prevent Tuberculosis
ROCKVILLE, Md., July 1 /PRNewswire-USNewswire/ -- The Aeras Global TB Vaccine Foundation today announced that James E. Connolly has been named President and Chief Executive Officer. He joins Aeras after a career in the pharmaceutical industry, most recently as Executive Vice President and General Manager of Wyeth Vaccines. He will take over as Aeras President and CEO on August 9, 2010.
"As Aeras continues its momentum to develop new tuberculosis vaccines for all who need them, we are delighted that Jim Connolly will lead the organization through its next phase," said R. Gordon Douglas, Jr., MD, the Executive Chairman of the Aeras Global TB Vaccine Foundation. "Jim has exactly the right mix of leadership and passion for Aeras' important, lifesaving mission. His management and financial expertise and his vaccine experience will be tremendous assets to Aeras as it advances its portfolio of TB vaccine candidates through late-stage trials and ultimately licensure and distribution." Dr. Douglas added that Jim Connolly's background, which includes efforts to expand access to vaccines in developing countries, will be valuable in working with Aeras' broad array of partners worldwide.
"Leading Aeras provides an exciting opportunity to apply all
that I have learned during more than twenty years in the
pharmaceutical industry to one of the world's most pressing
challenges: freeing the world of tuberculosis, which continues to
kill almost two million people each year," said Jim Connolly